Relapsed And Refractory clinical trials

Explore recruiting relapsed and refractory clinical trials.

Recruiting relapsed and refractory studies right now

Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record

Also recruiting in Europe

Relapsed And Refractory trials registered in the EU Clinical Trials Information System (CTIS). These are outside the "near me" matcher above - open a study for full details.

e-REVRI - A Phase 2 Study evaluating Epcoritamab in subjects with relapsed and refractory primary diffuse large B-cell lymphoma of the CNS treated with Lenalidomide and Rituximab

France

Phase II and Phase III (Integrated) EU CTIS Study details

Venetoclax and Dexamethasone in translocation (11;14) positive relapsed and refractory multiple myeloma (VICTORIA)

Denmark

Therapeutic exploratory (Phase II) EU CTIS Study details

A Phase 3, Open-Label Study to Evaluate Safety and Efficacy of Epcoritamab in Combination with Rituximab and Lenalidomide (R2) compared to R2 in Subjects with Relapsed or Refractory Follicular Lymphoma (EPCORE™ FL-1)

Denmark, Hungary, Slovakia, Sweden, Austria, Greece +8 more

Therapeutic confirmatory (Phase III) EU CTIS Study details

A trial to test if different amounts of KTX-1001 are safe and tolerable in people with the bone marrow cancer multiple myeloma that has come back or where treatment did not work.

Spain, France

Human Pharmacology (Phase I)- First administration to humans EU CTIS Study details

A Phase 1/2 Multicenter, Open-label Study to Assess the Safety, Pharmacokinetics and Efficacy of CC-92480 Monotherapy and in Combination with Dexamethasone in Subjects with Relapsed and Refractory Multiple Myeloma

Belgium, Spain

Therapeutic exploratory (Phase II) EU CTIS Study details

BOB1-TCR therapy for treatment of relapsed or refractory B-cell malignancies - A Phase 1/2 clinical trial

Netherlands

Phase I and Phase II (Integrated)- First administration to humans EU CTIS Study details

Relapsed And Refractory trials by city

Relapsed And Refractory in Toronto Relapsed And Refractory in Vancouver Relapsed And Refractory in Montreal Relapsed And Refractory in Calgary Relapsed And Refractory in Edmonton Relapsed And Refractory in Ottawa Relapsed And Refractory in Winnipeg Relapsed And Refractory in Quebec City Relapsed And Refractory in Hamilton Relapsed And Refractory in Kitchener Relapsed And Refractory in London Relapsed And Refractory in Halifax Relapsed And Refractory in New York Relapsed And Refractory in Los Angeles Relapsed And Refractory in Chicago Relapsed And Refractory in Houston

Other conditions

Obesity Type 2 diabetes Type 1 diabetes Prediabetes Weight loss Metabolic syndrome High cholesterol High triglycerides High blood pressure PCOS Hypothyroidism Thyroid disease Gout Fatty liver disease (NAFLD/NASH) Heart failure Coronary artery disease Atrial fibrillation Stroke Stroke recovery Peripheral artery disease Pulmonary hypertension Deep vein thrombosis Chronic kidney disease Diabetic kidney disease